In a potentially pivotal trial, PTC Therapeutics' experimental therapy for Huntington's disease (HD) met its primary endpoint, but questions about the data have raised doubts about the company's ...
More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved PTC's ...
It has been about a month since the last earnings report for PTC Inc. (PTC). Shares have added about 2.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...
PTC Industries (PTCIL)’s Q2FY26 EBITDA recovered to INR 257mn (+21% YoY), after a dismal Q1, as we believe TARC EBITDA losses would have reduced and ATL performance has improved. EBITDA margin, at ...
I've upgraded PTC Inc. to a Buy at ~$179 per share after strong FQ4 2025 results, robust customer contract growth, and improved shareholder returns. PTC's focus on product lifecycle management, ...
Constant Currency ARR Growth: 8.5% year-over-year. Free Cash Flow Growth: 16% year-over-year, totaling $857 million for fiscal '25. Revenue Contribution from Kepware and ThingWorx: Approximately $200 ...
PTC is selling off its IoT businesses, Kepware and ThingWorx, in order to hone its focus on SaaS and AI, according to CEO Neil Barua, as the conglomerate announced a sale of the operations to asset ...
Goldman Sachs flags PTC Industries as a key APAC pick driven by titanium and aerospace growth catalysts. Goldman Sachs has added PTC Industries in its latest APAC Conviction List. The global brokerge ...
TPG has agreed to acquire PTC’s industrial connectivity and IoT businesses. No financial terms were disclosed. Headquartered in Boston, PTC is a software company. Neil Barua serves as president and ...
NHPC is unwilling to sell its stake in the power trading joint venture although it had, while shelving its buyout plan, said power trading was not its core business. New Delhi: After NHPC Ltd dropped ...
The FDA rejected PTC Therapeutics' NDA for vatiquinone, citing insufficient efficacy evidence and requiring an additional study for resubmission. The MOVE-FA trial, a Phase II/III study, failed to ...
PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback